214 results on '"Carter, Lawrence P."'
Search Results
2. Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled Trial
3. A rapid change in magma plumbing taps porphyry copper deposit-forming magmas
4. Phase 1 study of latozinemab in progranulin‐associated frontotemporal dementia
5. Crystal mush dykes as conduits for mineralising fluids in the Yerington porphyry copper district, Nevada
6. Solriamfetol for the Treatment of Excessive Sleepiness in OSA: A Placebo-Controlled Randomized Withdrawal Study
7. Drug Discrimination Studies for Investigations on the Mechanisms of Action of GABAB Receptor Ligands
8. Evaluation of the effect of JZP-110 in patients with narcolepsy assessed using the Maintenance of Wakefulness Test censored to 20 minutes
9. Effects of solriamfetol on on-the-road driving in participants with narcolepsy: A randomised crossover trial
10. Impact of sodium oxybate, modafinil, and combination treatment on excessive daytime sleepiness in patients who have narcolepsy with or without cataplexy
11. Psychomotor Vigilance Performance in Participants with Excessive Daytime Sleepiness in Obstructive Sleep Apnea or Narcolepsy Compared with SAFTE-FAST Model Predictions
12. Effects of solriamfetol on on‐the‐road driving in participants with narcolepsy: A randomised crossover trial
13. Effects of solriamfetol on on‐the‐road driving performance in participants with excessive daytime sleepiness associated with obstructive sleep apnoea
14. Acute cognitive effects of high doses of dextromethorphan relative to triazolam in humans
15. Effects of solriamfetol on on-the-road driving performance in participants with excessive daytime sleepiness associated with obstructive sleep apnoea
16. Inhaled vs. oral alprazolam: subjective, behavioral and cognitive effects, and modestly increased abuse potential
17. Possible role for glutamic acid decarboxylase in fibromyalgia symptoms: A conceptual model for chronic pain
18. Principles of laboratory assessment of drug abuse liability and implications for clinical development
19. Case histories in pharmaceutical risk management
20. Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem ®): Differences in characteristics and misuse
21. Cognitive effects of intramuscular ketamine and oral triazolam in healthy volunteers
22. High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens
23. Cognitive, psychomotor, and subjective effects of sodium oxybate and triazolam in healthy volunteers
24. What would menthol smokers do if menthol in cigarettes were banned? Behavioral intentions and simulated demand
25. A Randomized, Double‐Blind, Placebo‐ and Positive‐Controlled, 4‐Period Crossover Study of the Effects of Solriamfetol on QTcF Intervals in Healthy Participants
26. Solriamfétol (JZP-110) pour le traitement de la somnolence diurne excessive (SDE) chez les patients avec narcolepsie avec et sans cataplexie : résultats d’un essai clinique de phase 3 randomisé
27. Effects of Solriamfetol on Quality-of-Life Measures from a 12-Week Phase 3 Randomized Controlled Trial
28. Solriamfetol for the Treatment of Excessive Daytime Sleepiness in Participants with Narcolepsy with and without Cataplexy: Subgroup Analysis of Efficacy and Safety Data by Cataplexy Status in a Randomized Controlled Trial
29. Measures of functional outcomes, work productivity, and quality of life from a randomized, phase 3 study of solriamfetol in participants with narcolepsy
30. Un essai randomisé contrôlé testant les olriamfétol dans la somnolence diurne excessive des syndromes d’apnées obstructives du sommeil
31. Étude randomisée, contrôlée testant le solriamfétol vs placebo dans la somnolence diurne excessive des narcolepsies de type 1 et 2
32. P003 Randomised, placebo-controlled study of solriamfetol for excessive daytime sleepiness in narcolepsy types 1/2
33. P004 Solriamfetol for excessive daytime sleepiness in obstructive sleep apnoea: a randomised controlled trial
34. The role of population size in the determination and prediction of population forecast errors: An evaluation using conifidence intervals for subcounty areas
35. Behavioral analyses of GHB: Receptor mechanisms☆
36. Comparison of the behavioral effects of gamma-hydroxybutyric acid (GHB) and its 4-methyl-substituted analog, gamma-hydroxyvaleric acid (GHV)
37. Lack of effects of GHB precursors GBL and 1,4-BD following i.c.v. administration in rats
38. Discriminative stimulus effects of flumazenil: perceptual masking by baclofen, and lack of substitution with gamma-hydroxybutyrate and its precursors 1,4-butanediol and gamma-butyrolactone
39. Discriminative stimulus effects of GHB and GABAB agonists are differentially attenuated by CGP35348
40. suppl._mat – Supplemental material for A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor
41. Pregnancy and Contraception Experiences in Women With Narcolepsy: A Narcolepsy Network Survey
42. 0618 Weight Change Associated with Solriamfetol Treatment of Excessive Daytime Sleepiness in Participants with Narcolepsy or Obstructive Sleep Apnea
43. 0570 Dose Titration Of Solriamfetol In Participants With Obstructive Sleep Apnea From A 6-week Randomized-withdrawal Trial
44. A randomized study of solriamfetol for excessive sleepiness in narcolepsy
45. Solriamfetol for the Treatment of Excessive Sleepiness in OSA
46. A Randomized, Double‐Blind, Placebo‐ and Positive‐Controlled, 4‐Period Crossover Study of the Effects of Solriamfetol on QTcF Intervals in Healthy Participants.
47. Amnestic effects of sodium oxybate are less than those of triazolam—reply to Drs. Zvosec and Smith
48. Erratum to: High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens
49. A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor
50. Characterization of the Neurochemical and Behavioral Effects of Solriamfetol (JZP-110), a Selective Dopamine and Norepinephrine Reuptake Inhibitor
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.